Cadila Healthcare's Company Signs 3 Share Purchase Agreements To Acquire Amplitude Surgical, Eyes Over 90 per cent Ownership Through Block Deal And Tender Offer

In a year, the stock has declined by 8 per cent while in last 3 years the stock has jumped by 151 per cent.

Zydus Lifesciences Limited has signed a share purchase agreement to acquire a majority stake in Amplitude Surgical SA. This follows a joint announcement made on March 11, 2025, and the completion of the mandatory information and consultation process with the works council of Amplitude SAS. Through the agreement, Zydus will acquire 75.4 per cent of the share capital of Amplitude at a price of EUR 6.25 per Amplitude share. The acquisition is from PAI Partners, Olivier Jallabert, and other managers of Amplitude.

Including two share purchase agreements already signed on March 11, 2025, with two minority shareholders, Zydus will acquire 85.6 per cent of the share capital of Amplitude. The completion of the Block Acquisition is subject to customary closing conditions. These conditions include authorization from the French Minister of Economy regarding foreign investments, the re-investment by Amplitude CEO Olivier Jallabert into the company, and the absence of qualified material adverse events. 

Zydus expects to complete the Block Acquisition by Q3 2025, subject to the fulfillment of the closing conditions. Following this, Zydus will file a mandatory simplified tender offer with the Autorité des Marchés Financiers (AMF). This will be followed by a squeeze-out procedure if the conditions are met. Commitments to tender 4.7 per cent of Amplitude's share capital have been executed with other minority shareholders of Amplitude, as announced on April 17, 2025. Consequently, Zydus anticipates acquiring more than 90 per cent of Amplitude's capital and voting rights after the tender offer, enabling them to implement a squeeze-out procedure. As of June 30, 2024, Amplitude Surgical employed 428 people and generated sales of nearly EUR 106.0 million. 

In the Quarterly Results of December 2024, the company reported a revenue of Rs 5,269.10 crore, reflecting a YoY growth of 16.96 per cent compared to Rs 4,505.20 crore in December 2023. The operating profit stood at Rs 1,387.60 crore, marking a 25.87 per cent increase from Rs 1,102.40 crore in the same quarter last year. The profit after tax (PAT) rose by 29.62 per cent to Rs 1,023.50 crore from Rs 789.60 crore in December 2023.

In FY24, the company posted a revenue of Rs 19,547.40 crore, registering a 13.40 per cent growth compared to Rs 17,237.40 crore in FY23. The net profit for the year stood at Rs 3,859.50 crore, up 96.88 per cent from Rs 1,960.30 crore in the previous financial year.

Zydus Lifesciences Ltd. is a global lifesciences company focused on discovering, developing, manufacturing, and marketing a broad range of healthcare therapies. The company employs over 27,000 individuals worldwide, including 1,400 scientists in R&D, and is committed to improving lives through quality healthcare solutions. Zydus aims to transform lives through innovative discoveries in the field of life sciences. In a year, the stock has declined by 8 per cent while in last 3 years the stock has jumped by 151 per cent.

Investors should keep an eye on this stock.

Disclaimer: The article is for informational purposes only and not investment advice.